

## GlycoMimetics Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Jan-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 2 Clinical..... 11

    Phase 1 Clinical..... 19

    Discovery..... 23

[Return to Table of Contents](#)

# GlycoMimetics Inc

## COMPANY OVERVIEW

Company Name	GlycoMimetics Inc
Parent Company Name	GlycoMimetics Inc
Website	<a href="http://www.glycomimetics.com/">http://www.glycomimetics.com/</a>
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	2
Number of Patents as Owner	24
Number of Patents as Third Party	0
Number of Deals	7
Key Indications	Inflammatory disease,Cancer,Acute myelogenous leukemia,Hematological neoplasm,Thromboembolism,Cardiovascular disease,Deep vein thrombosis,Metastasis,Pancreas tumor,Pseudomonas aeruginosa infection,Sickle cell crisis
Key Target-based Actions	E-Selectin antagonist,Cell adhesion molecule inhibitor,P-Selectin antagonist,CXCR4 chemokine antagonist,L-Selectin antagonist,Dendritic ICAM-3 grabbing nonintegrin 1 inhibitor,Selectin modulator,Unspecified cell adhesion molecule inhibitor
Key Technologies	Small molecule therapeutic,Intravenous formulation,Oral formulation,Biological therapeutic,Infusion,Nasal systemic formulation,Subcutaneous formulation,Peptidomimetic

## COMPANY PROFILE

### SUMMARY

GlycoMimetics Inc (GMI) is active in the field of glycobiology and develops small-molecule drugs that mimic the functions of certain carbohydrates. The company's initial focus is on therapeutics to treat inflammatory diseases and cancer.

### ACQUISITIONS AND SPIN-OFFS

By early 2003, GMI had acquired the assets of GlycoTech Corp, including exclusive rights to 15 issued US patents and numerous small molecules that could have therapeutic potential.

### COMPANY LOCATION

In August 2014, the company's headquarters was shifted to Medical Center Drive in Rockville, Maryland.

### FINANCIAL

In October 2013, GlycoMimetics filed a registration statement on Form S-1 with the US SEC for a proposed initial public offering of shares of its common stock. By that time, the company had applied to list its common stock on the NASDAQ Global Market under the ticker symbol 'GLYC'. In January 2014, the company priced the offering of 7,000,000 common stock shares at \$8.00 per share and granted a 30-day option to the underwriters to purchase up to an additional 1,050,000 common stock shares. At that time, the offering was expected to close on January 15, 2014; later that month, the offering of 8,050,000 shares was closed. The company raised net proceeds of approximately \$57.4 million.

In October 2009, GlycoMimetics raised \$38 million from a venture financing round.

In June 2006, GlycoMimetics raised an additional \$15.4 million from its series B financing. It planned to use the funds for preclinical development of its selectin inhibitors for inflammation and its lectin-binding glycomimetics for infection.

In August 2004, GlycoMimetics raised an additional \$5.1 million from an extension to a series A seed financing, bringing total proceeds to \$9.6 million. The funds would be used to advance the company's research programs.

[Return to Table of Contents](#)


In May 2003, GMI closed on its initial seed round of venture financing.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	1	4
Hematological disease	3	0	3
Inflammatory disease	2	1	3
Immune disorder	0	2	2
Infectious disease	1	1	2
Cardiovascular disease	2	0	2
Respiratory disease	0	1	1
Gastrointestinal disease	1	0	1
Genetic disorder	1	0	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	3
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	1	0	1
Drug - Funding	1	0	0	0	1
Drug - Early Research/Development	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Development Services	0	0	3	0	3

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Hematological disease	1	3
Genetic disorder	0	2
Neoplasm	1	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	1
Phase 1	2	5

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)





## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	10	0	10
Endocrine disease	3	0	3
Gastrointestinal disease	4	0	4
Hematological disease	12	0	12
Degeneration	1	0	1
Immune disorder	10	0	10
Musculoskeletal disease	2	0	2
Neoplasm	12	0	12
Ocular disease	1	0	1
Genetic disorder	3	0	3
Metabolic disorder	3	0	3
Neurological disease	2	0	2
Respiratory disease	3	0	3
Infectious disease	7	0	7
Injury	2	0	2
Inflammatory disease	14	0	14
Dermatological disease	5	0	5
Ulcer	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### rivipansel sodium

#### rivipansel sodium SNAPSHOT

<b>Drug Name</b>	rivipansel sodium
<b>Key Synonyms</b>	rivipansel sodium;rivipansel
<b>Originator Company</b>	GlycoMimetics Inc
<b>Active Companies</b>	GlycoMimetics Inc;Pfizer Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Sickle cell crisis
<b>Target-based Actions</b>	Cell adhesion molecule inhibitor;E-Selectin antagonist;P-Selectin antagonist;L-Selectin antagonist
<b>Other Actions</b>	Anticancer;Platelet aggregation inhibitor;Chemoprotectant;Anti-inflammatory
<b>Technologies</b>	Small molecule therapeutic;Subcutaneous formulation;Intravenous formulation;Infusion
<b>Last Change Date</b>	29-Dec-2014

#### rivipansel sodium DEVELOPMENT PROFILE

##### SUMMARY

GlycoMimetics and licensee Pfizer are developing rivipansel sodium (GMI-1070, PF-06460031, structure shown), the lead from a series of heterobifunctional glycomimetic pan-selectin inhibitors, for the potential iv and/or sc treatment of vaso-occlusive crisis associated with sickle cell disease.

In May 2010, a phase II trial for vaso-occlusive crisis of sickle cell disease began; in April 2013, positive topline data were reported. In July 2014, Pfizer had reached an agreement with the US FDA under a special protocol assessment (SPA) for a phase III trial for vaso-occlusive crisis of sickle cell disease; in August 2014, the phase III trial was to start in September 2014. In September 2014, the trial initiation was delayed due to the manufacturing development issue as notified by the Pfizer and the company would provide a timeframe regarding the initiation of the trial to GlycoMimetics.

GlycoMimetics was previously developing the drug for other indications. In October 2009, the drug was listed as in phase I development for hematological cancers by GlycoMimetics; this was still the case in February 2012. However, no further development for this indication has since been reported. GlycoMimetics was initially also investigating rivipansel sodium for the potential treatment of asthma; however, no development has been reported in asthma.

#### rivipansel sodium DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS


[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
GlycoMimetics Inc	Sickle cell crisis	Canada	Phase 2 Clinical	24-May-2010
GlycoMimetics Inc	Sickle cell crisis	US	Phase 2 Clinical	31-May-2009
Pfizer Inc	Sickle cell crisis	Canada	Phase 2 Clinical	11-Oct-2011
Pfizer Inc	Sickle cell crisis	US	Phase 2 Clinical	11-Oct-2011
Pfizer Inc	Sickle cell crisis	Belgium	Phase 1 Clinical	22-Dec-2014
GlycoMimetics Inc	Asthma	US	No Development Reported	22-Oct-2009
GlycoMimetics Inc	Hematological neoplasm	US	No Development Reported	31-Aug-2013


## rivipansel sodium CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
1189037-60-2	2



Name	Type
rivipansel sodium	USAN
GMI-1070	Research Code
PF-06460031	Research Code

CAS Registry Number:	Confidence Level:
927881-99-0	2



[Return to Table of Contents](#)

Name	Type
rivipansel	INN; USAN

### rivipansel sodium DRUG NAMES




Names	Type
heterobifunctional glycomimetic pan-selectin inhibitors (small molecule therapeutic), GlycoMimetics	
GMI-1077	Research Code
heterobifunctional glycomimetic pan-selectin inhibitors (small molecule therapeutic), GlycoMimetics/ Pfizer	
rivipansel sodium	USAN
rivipansel	INN, USAN
PF-06460031	Research Code
GMI-1011	Research Code
GMI-1010	Research Code
rivipansel sodium (sickle cell crisis), GlycoMimetics/ Pfizer	
selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics/ Pfizer	
glyosin, GlycoMimetics	
GMI-1040 series	
GMI-1070	Research Code
selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics	

[Return to Table of Contents](#)



rivipansel sodium SALES AND FORECASTS

CHARTS



## COMMENTARY

### CONSENSUS SALES INFORMATION

Consensus forecast data for Pfizer are presented.

### REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In October 2011, Pfizer acquired an exclusive worldwide license from GlycoMimetics for rivipansel sodium for vaso-occlusive crisis associated with sickle cell disease and other indications. Under the terms of the agreement, GlycoMimetics would remain responsible for completion of the ongoing phase II trial under Pfizer's oversight, and Pfizer would then assume all further development and commercialization responsibilities [1229751].

### rivipansel sodium CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Sickle cell anemia											
0	0	1	1	0	0	0	2	0	0	1	3
Sickle cell crisis											
0	0	0	0	0	1	0	0	0	0	0	1

#### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	0	1	0	4	0	0	1	6

#### Phase Definitions

##### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

##### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

##### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
GlycoMimetics Inc	1	0	1	0	2
University of Basel	1	0	0	0	1
Pfizer Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Development Services	1	0	1



PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
GlycoMimetics Inc	6	0	6
Pfizer Inc	2	0	2
Glycotech Corp	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	3
Product	2
Product (derivative)	1

[Return to Table of Contents](#)

## GMI-1271

### GMI-1271 SNAPSHOT

Drug Name	GMI-1271
Key Synonyms	
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Deep vein thrombosis;Metastasis;Acute myelogenous leukemia;Pancreas tumor;Thromboembolism
Target-based Actions	E-Selectin antagonist
Other Actions	Anticancer;Anti-inflammatory;Synergist
Technologies	Oral formulation;Small molecule therapeutic;Intravenous formulation
Last Change Date	06-Jan-2015

### GMI-1271 DEVELOPMENT PROFILE

#### SUMMARY

GlycoMimetics is developing GMI-1271, an E-selectin antagonist with a companion diagnostic, for the potential treatment of cancers that are associated with elevated risk of metastasis and thrombosis including pancreatic cancer and acute myelogenous leukemia (AML) and other blood disorders,,. In June 2014, a phase I trial for AML was initiated ; in November 2014, topline results were reported. At that time, the company expected to initiate a phase I/II trial in AML in the first quarter of 2015. In November 2014, a phase I trial was initiated in healthy subjects in the US. At that time, the trial was expected to complete in September 2016. In October 2014, the company was seeking to out license the drug.

The company was previously investigating small molecule glycomimetic E-selectin antagonists, for the potential oral treatment of diabetes related vascular inflammation. In May 2009, the program was in lead optimization stage ; however, in December 2011, no further development was reported.

### GMI-1271 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlycoMimetics Inc	Acute myelogenous leukemia	US	Phase 1 Clinical	19-Jun-2014
GlycoMimetics Inc	Deep vein thrombosis	US	Phase 1 Clinical	04-Nov-2014
GlycoMimetics Inc	Metastasis	US	Discovery	03-Aug-2012
GlycoMimetics Inc	Pancreas tumor	US	Discovery	03-Aug-2012

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
GlycoMimetics Inc	Thromboembolism	US	Discovery	03-Aug-2012
GlycoMimetics Inc	Diabetic angiopathy	US	No Development Reported	28-Dec-2011

## GMI-1271 DRUG NAMES

Names	Type
E-selectin antagonists (metastasis/pancreas cancer/thromboembolism), GlycoMimetics	
GMI-1271	Research Code
E-Selectin antagonists (oral, diabetic angiopathy), GlycoMimetics	

## GMI-1271 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Acute myelogenous leukemia											
0	0	0	0	0	0	1	1	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	2	3	0	0	2	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

GMI-1271 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
US Government	0	0	2	0	2
University of Michigan	2	0	0	0	2
GlycoMimetics Inc	1	0	1	0	2

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2
Drug - Development Services	1	0	1

## GMI-1051

### GMI-1051 SNAPSHOT

Drug Name	GMI-1051
Key Synonyms	
Originator Company	GlycoMimetics Inc
Active Companies	GlycoMimetics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Pseudomonas aeruginosa infection
Target-based Actions	
Other Actions	Bacterial pathogenicity factor modulator;Antibacterial;Unspecified drug target
Technologies	Nasal systemic formulation;Small molecule therapeutic
Last Change Date	12-Nov-2014

### GMI-1051 DEVELOPMENT PROFILE

#### SUMMARY

GlycoMimetics is investigating GMI-1051, a small molecule PA-I galactophilic lectin (PA-IL) and fucose-binding lectin (PA-IIL) binding agent, from a series of nasally administered, lectin virulence factor-binding compounds, for the potential treatment or prevention of infections caused by *Pseudomonas aeruginosa* in cystic fibrosis (CF) patients,. In May 2009, preclinical studies had begun . At that time, the company anticipated obtaining additional efficacy data and the initiation of clinical trials. In October 2009, the company was planning to develop GMI-1051 as an antibiotic adjunctive therapy . In February 2012, GMI-1051 was listed as being in preclinical development ; in January 2014, this was still the case. In June 2011, the company was seeking to outlicense the drug.

### GMI-1051 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlycoMimetics Inc	<i>Pseudomonas aeruginosa</i> infection	US	Discovery	22-Jun-2003

[Return to Table of Contents](#)




GMI-1051 DRUG NAMES

Names	Type
GMI-1051	Research Code
antibacterial (Pseudomonas aeruginosa), GlycoMimetics	
lectin antagonists (anti-infectives), GlycoMimetics	
lectin-binding glycomimetics (P aeruginosa infections), GlycoMimetics	

GMI-1051 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
GlycoMimetics Inc	1	0	1

[Return to Table of Contents](#)



Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

[Return to Table of Contents](#)

## E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics

### E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics SNAPSHOT

<b>Drug Name</b>	E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlycoMimetics Inc
<b>Active Companies</b>	GlycoMimetics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer;Cardiovascular disease;Inflammatory disease
<b>Target-based Actions</b>	E-Selectin antagonist
<b>Other Actions</b>	Anti-inflammatory;Anticancer;Cardiovascular agent
<b>Technologies</b>	Oral formulation;Small molecule therapeutic
<b>Last Change Date</b>	21-Jan-2014

### E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics DEVELOPMENT PROFILE

#### SUMMARY

GlycoMimetics is investigating small molecule therapeutics which inhibits E-selectin for the potential oral treatment of inflammatory diseases, cardiovascular disease and cancer. In February 2012, development of the program was ongoing ; in January 2014, the program was listed as being in preclinical development.

### E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlycoMimetics Inc	Cancer	US	Discovery	21-Jan-2014
GlycoMimetics Inc	Cardiovascular disease	US	Discovery	21-Jan-2014
GlycoMimetics Inc	Inflammatory disease	US	Discovery	03-Feb-2012

[Return to Table of Contents](#)

E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics

DRUG NAMES

Names	Type
E-selectin modulators (oral, inflammatory diseases), GlycoMimetics	
E-selectin inhibitors (oral, inflammatory disease/cardiovascular disease/cancer), GlycoMimetics	

## dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics

### dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics SNAPSHOT

<b>Drug Name</b>	dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlycoMimetics Inc
<b>Active Companies</b>	GlycoMimetics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hematological neoplasm;Inflammatory disease
<b>Target-based Actions</b>	E-Selectin antagonist;CXCR4 chemokine antagonist;Cell adhesion molecule inhibitor
<b>Other Actions</b>	Anti-inflammatory;Anticancer chemosensitizer
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	22-Jan-2014

### dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics DEVELOPMENT PROFILE

#### SUMMARY

GlycoMimetics is investigating a program of compounds, including GMI-1215 and GMI-1257, which inhibit the overlapping E-selectin and CXCR4 pathways, for the potential use as a chemosensitizer in the treatment of hematological cancers including acute myeloid leukemia and for the potential treatment of inflammatory diseases,. In December 2011, preclinical data were reported ; in January 2014, the program was still listed as being in preclinical development.

### dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlycoMimetics Inc	Hematological neoplasm	US	Discovery	12-Dec-2011
GlycoMimetics Inc	Inflammatory disease	US	Discovery	19-Dec-2011

[Return to Table of Contents](#)



**dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics DRUG NAMES**

Names	Type
GMI-1257	Research Code
dual E-selectin and CXCR4 inhibitors (hematological cancer/inflammation), GlycoMimetics	
GMI-1215	Research Code

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

